Welcome to our dedicated page for Genpact SEC filings (Ticker: G), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Genpact Limited (NYSE: G) SEC filings, including current reports, registration statements, and other disclosures filed with the U.S. Securities and Exchange Commission. Genpact describes itself as an agentic and advanced technology solutions company, and its filings offer detailed insight into how it applies process intelligence and artificial intelligence within its business, as well as how it structures its capital and governance.
Investors can review Form 8-K filings for information on material events such as quarterly financial results, leadership changes, board appointments, and financing transactions. For example, recent 8-Ks discuss third quarter 2025 financial results, appointments of directors and senior officers, and the completion of a public offering of 4.950% Senior Notes due 2030 by Genpact UK Finco plc and Genpact USA, Inc., guaranteed by Genpact and Genpact Luxembourg.
Genpact also uses shelf registration statements and prospectus supplements on Form S-3 to register securities offerings, as reflected in the documentation supporting its 2030 senior notes. Credit agreement guarantees and supplemental indentures are described in exhibits to these filings, outlining covenants, guarantees, and change-of-control provisions relevant to Genpact’s debt structure.
On Stock Titan, AI-powered tools can help summarize lengthy filings, highlight key terms in 10-K and 10-Q reports, and surface notable items from Form 4 insider transaction reports where applicable. Real-time updates from EDGAR ensure that new Genpact filings appear promptly, allowing users to monitor financial performance, capital markets activity, and corporate governance developments through the company’s official regulatory disclosures.
Genpact Limited Senior Vice President Sameer Dewan reported an equity award of 16,530 common share units on January 30, 2026. The filing shows these shares at a price of $0, reflecting a grant of unvested restricted share units under the Genpact Limited 2017 Omnibus Incentive Compensation Plan.
Each RSU converts into one Genpact common share as it vests. One-third of the award will vest on each of January 10, 2027, January 10, 2028, and January 10, 2029, contingent on continued service. Following this grant, Dewan beneficially owns 54,279 common shares directly.
Genpact Limited Senior Vice President Anil Nanduru received an equity award of 21,371 common shares in the form of restricted share units on January 30, 2026. The award was granted at a price of $0 per share and increased his beneficially owned common shares to 99,346, held directly.
The RSUs were granted under the Genpact Limited 2017 Omnibus Incentive Compensation Plan. Each RSU converts into one common share upon vesting. One-third of the shares will vest on each of January 10, 2027, January 10, 2028, and January 10, 2029, if he continues in service through each vesting date.
Genpact Limited’s President and CEO, Balkrishan Kalra, reported an equity compensation grant in the form of restricted share units. On January 30, 2026, he was awarded 106,575 common shares at a price of $0 per share, increasing his beneficial ownership to 497,260 common shares, held directly.
The award represents unvested restricted share units under the Genpact Limited 2017 Omnibus Incentive Compensation Plan. Each RSU converts into one common share upon vesting. One-third of the shares will vest on each of January 10, 2027, January 10, 2028 and January 10, 2029, contingent on his continued service through each vesting date.
Genpact Limited reported that Senior Vice President and Chief Human Resources Officer Piyush Mehta received an award of 24,716 common shares on January 30, 2026 at a price of $0 per share, reflecting a grant under the company’s 2017 Omnibus Incentive Compensation Plan.
The award represents unvested restricted share units, each convertible into one common share upon vesting. One-third of the units will vest on each of January 10, 2027, January 10, 2028 and January 10, 2029, subject to Mehta’s continued service. Following this grant, he beneficially owns 147,416 common shares directly.
Genpact Limited reported that Senior Vice President Riju Vashisht received an equity award of 21,371 common-share RSUs on January 30, 2026 at a price of $0 per share, reflecting a stock-based compensation grant rather than an open-market purchase.
Following this award, Vashisht beneficially owns 116,892 Genpact common shares in total. The RSUs vest in three equal installments, with one-third vesting on January 10, 2027, one-third on January 10, 2028, and the final third on January 10, 2029, subject to continued service.
Genpact Limited’s Chief Financial Officer Michael Hal Weiner received an equity award of 35,396 common shares on January 30, 2026. The award was granted at a price of $0 per share in the form of restricted share units under the Genpact Limited 2017 Omnibus Incentive Compensation Plan.
Each RSU converts into one common share upon vesting. One-third of the shares are scheduled to vest on each of January 10, 2027, January 10, 2028 and January 10, 2029, conditioned on his continued service. Following this grant, he beneficially owned 171,471 common shares in total.
Genpact Ltd President and CEO Balkrishan Kalra reported a tax‑withholding transaction involving 29,691 common shares. On 01/10/2026, 29,691 Genpact common shares were withheld at a price of $48.24 per share to pay taxes due upon the vesting of restricted share units granted under the Genpact Limited 2017 Omnibus Incentive Compensation Plan, in a transaction coded "F" and exempt under Rule 16b-3.
After this withholding, Kalra directly holds 390,685 common shares of Genpact. This event reflects shares being retained by the company for tax purposes rather than an open-market sale.
Genpact Ltd senior vice president Sameer Dewan reported two transactions in Genpact common shares. On January 10, 2026, 9,780 shares were withheld at $48.24 per share to cover taxes upon the vesting of restricted share units granted under the Genpact Limited 2017 Omnibus Incentive Compensation Plan. After this withholding, Dewan beneficially owned 52,837 shares directly.
On January 13, 2026, Dewan sold 15,088 common shares at a weighted average price of $46.65 per share, with actual sale prices ranging from $46.40 to $47.05. These sales were made under a Rule 10b5-1 trading plan adopted on September 15, 2025. Following the sale, Dewan directly held 37,749 Genpact common shares.
Genpact Limited senior vice president Anil Nanduru reported a tax-related share withholding tied to equity compensation. On January 10, 2026, 11,871 common shares of Genpact Limited were withheld at a price of $48.24 per share. The filing explains these shares were withheld to pay taxes upon the vesting of restricted share units granted under the Genpact Limited 2017 Omnibus Incentive Compensation Plan and are exempt under Rule 16b-3.
After this transaction, Nanduru beneficially owned 77,975 common shares, held directly. The activity reflects routine tax withholding on vested stock awards rather than an open-market purchase or sale.
Genpact Limited senior vice president Riju Vashisht reported two transactions in the company’s common shares. On January 10, 2026, 10,733 shares were withheld to cover taxes upon vesting of restricted share units under the Genpact Limited 2017 Omnibus Incentive Compensation Plan at a price of $48.24 per share. This was a tax-related withholding rather than an open-market sale.
On January 13, 2026, Vashisht sold 16,016 common shares at a weighted average price of $46.65 per share, with actual prices ranging from $46.40 to $47.05. These sales were executed under a pre-established Rule 10b5-1 trading plan adopted on September 11, 2025. After these transactions, Vashisht directly held 95,521 Genpact common shares.